Published on in Vol 9, No 10 (2020): October

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/23543, first published .
Safety and Efficacy of Convalescent Plasma to Treat Severe COVID-19: Protocol for the Saudi Collaborative Multicenter Phase II Study

Safety and Efficacy of Convalescent Plasma to Treat Severe COVID-19: Protocol for the Saudi Collaborative Multicenter Phase II Study

Safety and Efficacy of Convalescent Plasma to Treat Severe COVID-19: Protocol for the Saudi Collaborative Multicenter Phase II Study

Journals

  1. Al Mutair A, Alhumaid S, Alhuqbani W, Zaidi A, Alkoraisi S, Al-Subaie M, AlHindi A, Abogosh A, Alrasheed A, Alsharafi A, Alhuqbani M, Alhowar N, Salih S, Alhedaithy M, Al-Tawfiq J, Al-Shammari H, Abdulqawi R, Ismail A, Hamdan N, Saad F, Olhaye F, Eltahir T, Rabaan A, Al-Omari A. Clinical, epidemiological, and laboratory characteristics of mild-to-moderate COVID-19 patients in Saudi Arabia: an observational cohort study. European Journal of Medical Research 2020;25(1) View
  2. Peng H, Rhind S, Beckett A. Convalescent Plasma for the Prevention and Treatment of COVID-19: A Systematic Review and Quantitative Analysis. JMIR Public Health and Surveillance 2021;7(4):e25500 View
  3. Raturi M, Kala M, Das K, Kusum A. Reviewing the Ethical Concerns of the Convalescent Plasma Therapy in COVID-19. Journal of Laboratory Physicians 2021;13(01):091 View
  4. Piechotta V, Iannizzi C, Chai K, Valk S, Kimber C, Dorando E, Monsef I, Wood E, Lamikanra A, Roberts D, McQuilten Z, So-Osman C, Estcourt L, Skoetz N. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review. Cochrane Database of Systematic Reviews 2021;2021(5) View